<code id='570052D6C3'></code><style id='570052D6C3'></style>

<acronym id='570052D6C3'></acronym>

<center id='570052D6C3'><center id='570052D6C3'><tfoot id='570052D6C3'></tfoot></center><abbr id='570052D6C3'><dir id='570052D6C3'><tfoot id='570052D6C3'></tfoot><noframes id='570052D6C3'>

<optgroup id='570052D6C3'><strike id='570052D6C3'><sup id='570052D6C3'></sup></strike><code id='570052D6C3'></code></optgroup>

<b id='570052D6C3'><label id='570052D6C3'><select id='570052D6C3'><dt id='570052D6C3'><span id='570052D6C3'></span></dt></select></label></b><u id='570052D6C3'></u>

~~<i id='570052D6C3'><strike id='570052D6C3'><tt id='570052D6C3'><pre id='570052D6C3'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

entertainment

author：entertainment 2025-10-02 04:40:45 Page View：15

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

advertisement

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

explore

Bright Health sells Medicare Advantage business to Molina

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

A look at other Americans who have crossed into North Korea over the years

A look at other Americans who have crossed into North Korea over the years

FILE-MatthewMiller,aU.S.citizen,sitsonthedockattheSupremeCourtduringhistrialinPyongyang,NorthKoreaon

Peter Hotez and the public health issue of online harassment

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Albert Bourla of Pfizer: worst biopharma CEO of 2023

HyacinthEmpinado/STATPfizeristhisyear’santi-EliLilly.IfDavidRicksisthebestbiopharmaCEOof2023,thenPfi

read more